SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
Don’t Chase American Virtual Cloud Technologies Higher
3 Stocks With Market-Beating Price Performance
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
Don’t Chase American Virtual Cloud Technologies Higher
3 Stocks With Market-Beating Price Performance
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
Don’t Chase American Virtual Cloud Technologies Higher
3 Stocks With Market-Beating Price Performance
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
Don’t Chase American Virtual Cloud Technologies Higher
3 Stocks With Market-Beating Price Performance
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
NASDAQ:EARS

Auris Medical - EARS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$0.28
$0.30
50-Day Range
$2.25
$3.27
52-Week Range
$0.73
$6.60
Volume
57,754 shs
Average Volume
3.10 million shs
Market Capitalization
$3.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EARS stock logo

About Auris Medical (NASDAQ:EARS) Stock

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Receive EARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Auris Medical and its competitors with MarketBeat's FREE daily newsletter.

EARS Stock News Headlines

What Is Ear Seeding Auriculotherapy?
What Causes Ear Pain While Flying?
See More Headlines

Receive EARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Auris Medical and its competitors with MarketBeat's FREE daily newsletter.

EARS Company Calendar

Last Earnings
5/11/2017
Today
10/07/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EARS
Fax
N/A
Employees
132,200
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.57 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.33 million
Optionable
Not Optionable
Beta
1.17

Key Executives

  • Thomas Meyer
    Chairman & Chief Executive Officer
  • Elmar Schärli
    Chief Financial Officer
  • Samuel A. Wickline
    Chief Scientific Officer
  • Andrea Vondraskova
    Medical Director













EARS Stock - Frequently Asked Questions

How were Auris Medical's earnings last quarter?

Auris Medical Holding Ltd. (NASDAQ:EARS) issued its quarterly earnings data on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $1.60.

When did Auris Medical's stock split?

Auris Medical shares reverse split on the morning of Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 30th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Auris Medical own?
What is Auris Medical's stock symbol?

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

What is Auris Medical's stock price today?

One share of EARS stock can currently be purchased for approximately $0.29.

How much money does Auris Medical make?

Auris Medical (NASDAQ:EARS) has a market capitalization of $3.33 million.

How many employees does Auris Medical have?

The company employs 132,200 workers across the globe.

How can I contact Auris Medical?

Auris Medical's mailing address is Clarendon House 2 Church Street, Hamilton D0, HM 11. The official website for the company is www.aurismedical.com. The biotechnology company can be reached via phone at (441) 295-5950 or via email at investors@aurismedical.com.

This page (NASDAQ:EARS) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.